Healthcare Featured

Merck's New Cholesterol Pill Is a Bet on a Drug Class That Already Failed Twice

The FDA just cleared the first cholesterol-lowering pill as powerful as the injectable drugs that flopped a decade ago. Merck needs it to help fill a $30 billion hole — and the math is harder than the headlines suggest.

Alpha One

30 Jul 2026 • 6 min read

On July 16, the FDA approved a small white pill that lowers LDL cholesterol by nearly 60% — matching the most powerful injectable drugs on the market. Merck's Lipfendra (enlicitide) is the first oral PCSK9 inhibitor ever cleared, and the headlines wrote themselves: a once-daily tablet, no needles, for the tens of millions of Americans whose statins aren't enough.

It is a genuine scientific milestone. It may also be a warning about how easily a great drug becomes a mediocre business.

Because the PCSK9 story has been told before — twice — and both times it ended in disappointment. Understanding why is the difference between reading this approval as Merck's next blockbuster and reading it as a very expensive bet on cracking a market that has already broken two of the industry's biggest players.

The class that was supposed to be worth $150 billion

Rewind to 2015. The FDA approved two injectable PCSK9 inhibitors within weeks of each other: Amgen's Repatha and the Sanofi-Regeneron drug Praluent. The science was spectacular — these were antibody drugs that knocked LDL down by 50% to 60% on top of statins, in exactly the high-risk cardiovascular patients who needed it most.

Wall Street lost its mind. The pharmacy-benefit manager CVS Health publicly warned the two drugs could cost the US health system $150 billion a year. Analysts penciled in multibillion-dollar franchises for each.

Then reality arrived. In 2017 — two full years after launch — global Repatha sales were $319 million and Praluent managed $195 million. Not billions. Hundreds of millions, combined, against a $150 billion fear.

The problem was never the science. It was the plumbing of American healthcare. At a list price above $14,000 a year, insurers and PBMs threw up prior-authorization walls. Doctors gave up filling out the paperwork. Medicare patients abandoned filled prescriptions at the pharmacy counter roughly 70% of the time — the drug was approved, covered on paper, and still didn't get taken. Amgen eventually cut Repatha's list price 60% to $5,850; Sanofi and Regeneron matched it. Sales barely moved. Sanofi ultimately walked away from the US cardiovascular market entirely.

That is the class Merck just re-entered.

Briefings like this land in members' inboxes before the market prices them in. Join free →

Why Merck thinks a pill changes the math

Merck's bet is that the injectables didn't fail because of the mechanism — they failed because of the delivery and the access friction around it. Fix those, the thesis goes, and you unlock the mass market that was there all along.

There is a real argument here. A pill is not a subcutaneous injection every two to four weeks. It slots into the exact prescribing habit that built the statin market — write a script, pick it up at CVS, take it with breakfast. Primary-care physicians who never touched an injectable biologic will write an oral cardiovascular drug without a second thought. And Merck priced Lipfendra at $10.50 a day — about $315 a month, roughly $3,800 a year — well below where the injectables launched, and it says most patients, including the majority of Medicare enrollees, will pay less than that out of pocket.

Merck's ambition is enormous. The company has run one of the largest cardiovascular outcomes programs in history — the CORALreef trials — enrolling over 14,500 patients to prove the drug doesn't just move a lab number but actually prevents heart attacks and strokes. If it works, the addressable population isn't the narrow slice the injectables fought over. It's a meaningful share of the tens of millions of Americans on statins who still can't get their LDL to target.

That is the bull case. It is not a crazy one.

The three things that have to go right

But notice what the bull case quietly assumes.

First, that the pill overcomes payer friction the price cuts never did. The injectables got cheaper and still didn't sell, because the wall wasn't only price — it was the PBM step-therapy machinery that forces patients through statins and other options first, plus the sheer effort of the prior-auth process. An oral formulation removes the needle objection. It does not, by itself, remove the utilization-management apparatus that PBMs use precisely to control spending on any large, expensive new category. A pill that 40 million people could take is a pill that PBMs have every incentive to gate.

Second, that the outcomes data actually arrives — years from now. Cardiologists learned from the PCSK9 era to demand proof of cardiovascular benefit, not just LDL reduction, before prescribing broadly. Lipfendra's decisive trial, CORALreef Outcomes, doesn't reach its primary completion until late 2029, with full readout into 2031. Until then, Merck is selling a surrogate — a cholesterol number — into a physician base that has been trained to wait for the hard endpoint. The blockbuster case and the proof of the blockbuster case are separated by roughly four years.

Third, that even a success meaningfully matters to Merck. This is the part the "first-ever pill" coverage misses. Analysts model peak Lipfendra sales around $5 billion by the mid-2030s — and even that assumes the mass market materializes. Set that against the hole Merck is actually staring at: Keytruda, the best-selling drug in the world, did roughly $31.7 billion in 2025 and represents more than half the company's business. Its core US patent expires in 2028. Biosimilars will start carving into $25 billion-plus of annual revenue almost immediately.

So the real framing is this: Merck's marquee 2026 launch, if everything breaks right over the next decade, replaces about one-sixth of the revenue it's about to lose from a single drug. Lipfendra isn't the answer to the Keytruda cliff. It's one brick in a wall Merck has to build very quickly, alongside its subcutaneous Keytruda Qlex reformulation, its oncology pipeline, and a wave of dealmaking.

What it means for your money

For investors, the Lipfendra approval is a useful lens on a bigger question: whether Merck's post-Keytruda strategy is a collection of singles or a genuine franchise-sized bet.

Watch three signals over the next 18 months. Prescription volume and payer coverage in the first few quarters will tell you fast whether the pill is escaping the injectables' access trap or repeating it — early scripts are the tell, not the launch price. Any interim CORALreef commentary matters because physician adoption is hostage to the outcomes data; a clean safety and efficacy signal accelerates uptake, any wobble freezes it. And Merck's M&A pace is the honest indicator of management's own confidence — the more aggressively it buys, the more it is telling you the internal pipeline, Lipfendra included, isn't big enough to cover the cliff on its own.

The temptation with a first-in-class drug is to price the science and forget the system it has to sell into. The PCSK9 class already ran that experiment. The molecule was never the problem. Whether Merck has solved everything around the molecule is the only question that matters — and the market won't have a real answer until the numbers behind the wall of American healthcare come back in.

For now, the pill is a milestone. The blockbuster is a hypothesis.

If this analysis was useful, this is what AlphaBriefing does every day — geopolitics and markets, connected to what it means for your money. Free members get the daily brief in their inbox; paid members get the investment frameworks, scenario pricing, and catalyst calendars behind the paywall.

Sign up free → — upgrade whenever it earns it.

Sources & Further Reading

Disclaimer

AlphaBriefing is an independent intelligence publication. The content in this article is produced for informational and educational purposes only. Nothing published by AlphaBriefing constitutes financial, investment, legal, tax, or regulatory advice, nor should it be construed as a solicitation or recommendation to buy, sell, or hold any security, asset, or financial instrument.

All views expressed are those of the author at the time of writing and are subject to change without notice. Markets are volatile and unpredictable; past performance is not indicative of future results. Any investment involves risk, including the possible loss of principal.

AlphaBriefing and its principals, employees, or contributors may hold positions in securities or assets mentioned in this article. This should be considered a potential conflict of interest. No material relationship with any company referenced exists unless explicitly disclosed. Readers should conduct their own due diligence and consult qualified financial, legal, and tax advisors before making any investment decisions.

Information in this article is drawn from public sources believed to be reliable at the time of publication. AlphaBriefing makes no warranty, express or implied, as to the accuracy, completeness, or timeliness of any information herein. AlphaBriefing accepts no liability for any loss or damage arising from reliance on this content.